Cytek BioSciences Inc(CTKB) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 4:01 PM ET (Korea 10/28 05:01)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.63 | Insider Own | 8.48% | Shs Outstand | 130.0M | Perf Week | 11.99% |
| Market Cap | 0.78B | Forward P/E | - | EPS next Y | 25.24% | Insider Trans | - | Shs Float | 119.0M | Perf Month | 4.18% |
| Enterprise Value | 0.55B | PEG | - | EPS next Q | -0.07 | Inst Own | 63.04% | Short Float | 3.71% | Perf Quarter | 36.53% |
| Income | -0.08B | P/S | 3.76 | EPS this Y | 33.97% | Inst Trans | -5.31% | Short Ratio | 3.9 | Perf Half Y | 30.85% |
| Sales | 0.21B | P/B | 2.41 | EPS next 5Y | 25.5% | ROA | -17.14% | Short Interest | 4.41M | Perf YTD | 18.42% |
| Book/sh | 2.48 | P/C | 2.97 | EPS past 3/5Y | - | ROE | -23.04% | 52W High | -3.7% ($6.21) | Perf Year | 44.1% |
| Cash/sh | 2.02 | P/FCF | - | Sales past 3/5Y | 7.1% 16.76% | ROIC | -23.55% | 52W Low | 80.66% ($3.31) | Perf 3Y | 38.11% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -1130% | Gross Margin | 53.23% | Volatility(W/M) | 5.57% 5.33% | Perf 5Y | -74.33% |
| Dividend TTM | - | EV/Sales | 2.66 | Sales Y/Y TTM | 5.44% | Oper. Margin | -21.6% | ATR (14) | 0.27 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.86 | EPS Q/Q | -113.41% | Profit Margin | -38.98% | RSI (14) | 66.58 | Recom | 1.67 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.48 | Sales Q/Q | 5.57% | SMA20 | 7.81% ($5.55) | Beta | 1.16 | Target Price | $6.17 |
| Payout | - | Debt/Eq | 0.11 | Earnings | 2026/11/4 | SMA50 | 15.29% ($5.19) | Rel Volume | 1.07 | Prev Close | $5.89 |
| Employees | 700 | LT Debt/Eq | 0.06 | EPS/Sales Surpr. | 3.54% 1.76% | SMA200 | 28.73% ($4.65) | Avg Volume(3M) | 1.13M | Price | $5.98 |
| IPO | 2021/7/23 | Option/Short | Yes/Yes | Trades | 7696 | Volume | 1,207,680 | Change | 1.53% |
🔬 Cytek Biosciences is a medical device company that develops and sells fluorescence-based cell analysis (flow cytometry) equipment. Through its Aurora and Northern Lights series, which incorporate full-spectrum technology, the company targets the life science research and clinical analysis markets. Alongside equipment sales, it has a recurring revenue structure that extends into reagents and services.
Over the past 1 year, on the higher side
4% below its 1-year high.
Traded about as much as usual. That is 107% of its average volume.
Next earnings report: November 4
7 days to go.
CTKB has a sound balance sheet but weak earning power
Of every $100 in sales, $21.60 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +34.0% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $376. Peers typically go for $336.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -74.3%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 63.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #50 of 142 in the industry
Based on market cap of $777M.
AHCO#47 AdaptHealth Corp $798M PER - 
VREX#48 Varex Imaging Corp $783M PER 35.4 
INMD#49 Inmode Ltd $781M PER 11.0 CTKB#50 Cytek BioSciences Inc $777M PER - 
PACB#51 Pacific Biosciences of California Inc $762M PER - 
FAQ
What kind of company is CTKB?
CTKB belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of CTKB?
The market cap of CTKB is approximately $777M, ranking 2,786 within its sector.
What is the 52-week high and low for CTKB?
CTKB has recorded a 52-week high of $6.21 and a low of $3.31.
